10-KPeriod: FY2021

QUEST DIAGNOSTICS INC Annual Report, Year Ended Dec 31, 2021

Filed February 28, 2022For Securities:DGX

Summary

Quest Diagnostics Inc. (DGX) reported robust performance in its 2021 10-K filing, demonstrating its critical role in the healthcare ecosystem. The company, a leading provider of diagnostic information services, generated $10.8 billion in net revenues for the year. Quest Diagnostics played a significant role in the COVID-19 pandemic response, performing approximately 63 million diagnostic and antibody tests. The company's strategy focuses on accelerating growth through strategic acquisitions, capitalizing on increased health plan access, growing its Advanced Diagnostics segment, and building consumer-initiated testing. Looking ahead, Quest Diagnostics is committed to operational excellence, aiming to improve efficiency and customer experience through digitization and automation. The company's strengths lie in its quality, extensive assets and capabilities, innovation, and customer focus. Despite a competitive landscape and evolving healthcare system, Quest Diagnostics is well-positioned to benefit from industry trends such as consolidation and the increasing focus on value-based care, while continuing its disciplined capital deployment strategy including dividends and share repurchases.

Financial Highlights

56 data points
Beta

Revenue

$10.79B

39.0% Gross Margin

Net Income

$2.00B

18.5% Net Margin

EPS (Diluted)

$15.55

Total Assets

$13.61B

Cash & Equivalents

$872.00M

Free Cash Flow

$1.83B

Financial Statements
Beta
Revenue$10.79B
Cost of Revenue$6.58B
Gross Profit$4.21B
SG&A Expenses$1.73B
Operating Expenses$8.41B
Operating Income$2.38B
Interest Expense$152.00M
Net Income$2.00B
EPS (Basic)$15.85
EPS (Diluted)$15.55
Shares Outstanding (Basic)125.00M
Shares Outstanding (Diluted)128.00M

Key Highlights

  • 1Achieved $10.8 billion in net revenues for 2021, highlighting strong market position and service demand.
  • 2Demonstrated significant contribution to public health by performing approximately 63 million COVID-19 related diagnostic and antibody tests.
  • 3Focused on a two-point business strategy: Accelerate Growth (acquisitions, health plan partnerships, advanced diagnostics, consumer testing) and Drive Operational Excellence (efficiency, digitization, automation).
  • 4Reinforced its commitment to shareholders by announcing an approximate 6.5% increase in its quarterly cash dividend and continuing its share repurchase program.
  • 5Leveraged its extensive network and data assets to drive innovation and provide integrated solutions across its clinical franchises.
  • 6Navigated a complex regulatory and competitive environment by emphasizing quality, operational efficiency, and customer focus.

Frequently Asked Questions

Quest Diagnostics reported net revenues of $10.8 billion for the fiscal year ended December 31, 2021.

The company played a pivotal role by performing approximately 63 million molecular diagnostic and antibody tests for COVID-19, and has built substantial testing capacity to handle demand surges.

Quest Diagnostics' strategy has two main pillars: Accelerate Growth (through strategic acquisitions, partnerships with health plans, expanding Advanced Diagnostics, and developing consumer-initiated testing) and Drive Operational Excellence (focusing on efficiency, digitization, and automation to enhance customer experience and reduce costs).

The company practices disciplined capital deployment, which includes investing in its business, paying dividends, and repurchasing shares. In February 2022, they announced an increase in their quarterly dividend by approximately 6.5% and have a consistent share repurchase program.